Why the study?
Does indapamide 1.25 mg/day reduce sitting diastolic blood pressure in elderly patients with mild to moderate essential hypertension?
Does indapamide 1.25 mg/day reduce sitting diastolic blood pressure in elderly patients with mild to moderate essential hypertension?
Low-dose indapamide (1.25 mg/day) effectively reduces blood pressure in elderly patients with mild to moderate hypertension without clinically significant metabolic adverse effects.
Answers are grounded in this paper and cite their sources.
Supports low-dose indapamide for BP control in elderly hypertensives; confirms placebo-controlled efficacy in mild-to-moderate hypertension.
A low dose (1.25 mg) of indapamide (Lozol®, Rhône‐Poulenc Rorer Pharmaceuticals, Collegeville, PA) was evaluated in 222 elderly patients (≥50 years) with mild to moderate essential hypertension in a multicenter, randomized, double‐blind, parallel‐group clinical trial. A 4‐week single‐blind placebo washout period was followed by an 8‐week double‐blind treatment period. Patients were randomized to receive indapamide 1.25 mg/day or to receive placebo. The primary efficacy variable was the mean change in sitting diastolic blood pressure from baseline to week 8. Eighty‐one patients in the indapamide group (73%) and 87 patients in the placebo group (78%) completed the 8 weeks of double‐blind therapy. Therapy with 1.25 mg of indapamide produced greater reductions compared with placebo in sitting diastolic blood pressure after 8 weeks of therapy, with statistical significance (P ≤ 0.0015) seen after only 2 weeks of therapy and continuing throughout the 8 weeks. All secondary efficacy measures (sitting systolic blood pressure, standing systolic and diastolic blood pressures, and ≥ 10 mm Hg decrease or final value of ≤ 90 mm Hg in sitting diastolic blood pressure) also showed superior (P ≤ 0.0014) improvement in the indapamide group compared with placebo after 8 weeks of double‐blind treatment. During the 8‐week double‐blind treatment period, incidence rates for all adverse events and for drug‐related adverse events were similar between the two treatment groups. Among patients who received indapamide, the only drug‐related adverse events that occurred with an incidence of ≥ 2% were headache (4%), dizziness (4%), asthenia (2%), pain (2%), abnormal vision (2%), and impotence (2%). Similar incidence rates for these adverse events were seen in the placebo group. Among indapamide patients, mean changes in potassium (–0.27 mEq/L), uric acid (0.76 mg/dL), and BUN (1.42 mg/dL) were noted but not clinically significant .
No takes yet. Share an insight, caveat, or question.
Weidler et al. (1995) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: